How to Value an Ambulatory Surgery Center (ASC) in 2026

Ambulatory surgery centers are among the most attractive healthcare assets in today's M&A market. Our database of 154 ASC transactions shows a median EBITDA multiple of 7.9x and a revenue multiple of 1.9x — but those medians mask enormous variation. A single-specialty ASC doing $3M in revenue might sell for 5x EBITDA. A multi-specialty platform with orthopedic and cardiac cases, strong commercial payer mix, and 10,000+ annual cases can command 10-12x or higher.

Having advised on healthcare transactions throughout my career, I can tell you that ASC valuation is more nuanced than almost any other healthcare vertical. The interplay between physician ownership, case mix, payer dynamics, real estate, and regulatory requirements creates a valuation puzzle that requires deep industry knowledge to solve correctly.

Why ASCs Are So Attractive to Buyers

The secular trend driving ASC valuations is the migration of procedures from inpatient hospital settings to outpatient ambulatory facilities. CMS has been steadily expanding the list of procedures approved for ASC settings, and commercial payers strongly prefer ASCs because the same procedure costs 40-60% less than in a hospital outpatient department (HOPD).

This trend creates a virtuous cycle for ASC owners: more approved procedures means more case volume, which means more revenue, which attracts more physician partners, which drives more cases. The best ASCs I've valued are growing 8-15% annually just from the organic expansion of cases that can now be done in an outpatient setting.

The major platform acquirers — USPI (Tenet), SCA Health (Optum/UnitedHealth), AmSurg (Envision) — are among the most sophisticated and well-capitalized buyers in all of healthcare M&A. They're competing aggressively for high-quality ASCs, which supports premium valuations for centers that meet their criteria.

The Metrics That Drive ASC Valuation

Case Volume and Mix

Case volume is the top-line metric, but case mix is where the real value lies. Not all surgical cases are equal. The specialties that drive the highest ASC valuations are, in rough order of impact:

Orthopedics (especially total joints): The addition of total knee and total hip replacements to the ASC-approved list was a game-changer. These are high-reimbursement cases ($15,000-$25,000 per case) with strong commercial payer rates. An ASC performing 200+ total joints annually is extremely attractive to platform buyers.
Ophthalmology: High-volume, fast-turnaround cataract and retinal cases. Lower per-case revenue ($1,500-$3,000) but exceptional throughput — a busy ophthalmic ASC can do 30-40 cases per day. The volume creates attractive economics.
Spine: Increasingly migrating to ASC settings. High reimbursement per case ($10,000-$20,000+) but requires specialized equipment and highly skilled surgeons.
Cardiology: The newest frontier. CMS added certain cardiac catheterization procedures to the ASC-approved list, and this specialty is expected to be a major growth driver over the next 5 years.
GI/Endoscopy: The workhorse of many ASCs. Colonoscopies and upper endoscopies are high-volume, moderate-reimbursement ($800-$1,500) procedures. GI-focused ASCs trade at somewhat lower multiples because the cases are less complex and more easily replicated.

A multi-specialty ASC with a strong orthopedic and/or ophthalmology program commands a premium over a single-specialty GI center, even at similar revenue levels, because the higher-acuity cases generate better margins and are harder for competitors to replicate.

Payer Mix

Payer mix is the second most important valuation driver after case volume/mix. Commercial insurance pays ASCs 2-4x what Medicare pays for the same procedure. An ASC with 60%+ commercial payer mix is a fundamentally different business than one that's 60% Medicare/Medicaid.

I've seen ASCs with identical case volumes trade at materially different multiples based on payer mix alone. A center doing 5,000 cases with 65% commercial mix might generate $12M in net revenue and $3M in EBITDA. The same 5,000 cases at 65% Medicare might generate $7M in net revenue and $1.2M in EBITDA. The commercial-heavy center is worth nearly three times as much.

Managed care contracting is therefore critical. ASCs with out-of-network billing strategies face increasing risk as payers push balance billing protections and network adequacy requirements. In-network contracts at favorable rates are more sustainable and more valuable to buyers.

Physician Ownership and Syndication

Most ASCs operate as physician-owned joint ventures, and the ownership structure significantly impacts both valuation and deal complexity. Understanding this is essential.

The physician alignment model. When physicians own equity in the ASC, they have a direct financial incentive to bring their cases there rather than to the hospital. This alignment is what makes ASCs work. A center where the top 5 surgeons each own 10-15% of the entity has built-in case volume stability. As long as those physicians maintain their practices, the cases keep flowing.

The key-physician risk. The flip side of physician ownership is concentration risk. If one or two surgeons account for 40%+ of cases, the ASC has a concentration problem that buyers will scrutinize. A physician's retirement, relocation, disability, or decision to take cases elsewhere can devastate an ASC's revenue. Buyers typically require employment agreements or case volume commitments from key physicians as a condition of closing.

Syndication complexity. Selling an ASC isn't like selling a single-owner business. With 10-20 physician partners, you need to achieve consensus on deal terms, manage competing interests (some physicians want to sell, others don't), and navigate Stark Law and Anti-Kickback Statute compliance in structuring the transaction. I've seen ASC deals take 12-18 months to close primarily because of syndication dynamics, not buyer negotiations.

The typical deal structure involves the platform buyer (USPI, SCA Health, etc.) acquiring a majority stake (51-70%) while physicians retain a minority interest. The physicians continue to bring cases and share in the economics, while the platform provides capital, management infrastructure, and payer contracting leverage. This structure usually generates the highest total value because it preserves physician alignment.

Size Brackets and What Our Data Shows

Our transaction data reveals a clear size premium in ASC valuations:

Under $5M revenue: 5.5x EBITDA, 1.2x revenue. Small, often single-specialty centers with limited buyer interest. Typically GI or pain management focused.
$5-25M revenue: 7.4x EBITDA, 1.8x revenue. The most active transaction range. Multi-specialty centers with 3,000-10,000 annual cases. Attracts platform buyers and health system partners.
$25M+ revenue: 9-12x EBITDA, 2.0-3.0x revenue. Large, multi-room centers or small platforms. Premium multiples driven by scale, operational sophistication, and competitive buyer interest.

The jump from under $5M to the $5-25M bracket represents a nearly 2x multiple expansion on EBITDA. For smaller ASC operators, the implication is clear: growth to the $5M+ revenue threshold — through adding specialties, recruiting surgeons, or adding procedure rooms — can dramatically increase enterprise value.

Health System Joint Ventures

An increasingly common ASC structure is the joint venture between physicians and a health system. These JVs have unique valuation dynamics. The health system partner provides referral channels, managed care contracts (often at hospital-level rates applied to ASC-cost procedures, which creates outsized margins), and political cover with state regulators.

ASCs with health system JV partners can trade at premiums because the health system relationship provides revenue stability, payer leverage, and regulatory support. However, the JV agreement itself needs careful review — some give the health system partner veto rights, ROFR on sale, or other provisions that can complicate a transaction or suppress competitive bidding.

Regulatory and Licensing Considerations

ASCs operate in a heavily regulated environment, and regulatory status directly impacts valuation:

Medicare certification. Medicare-certified ASCs can bill Medicare directly and must comply with CMS Conditions for Coverage. Certification is valuable because it opens the Medicare payer channel and signals regulatory compliance. Gaining certification takes 6-12 months, so an already-certified center has a meaningful head start.

State CON requirements. Roughly half of states require a Certificate of Need to establish or expand an ASC. In CON states, the certificate itself has standalone value — it represents a barrier to entry that limits competition. I've seen CON valuations range from $500K to $3M+ depending on the state and market, and the CON is often the most valuable asset in smaller ASC transactions.

Accreditation. AAAHC (Accreditation Association for Ambulatory Health Care) or Joint Commission accreditation is increasingly required by commercial payers and is a baseline expectation for institutional buyers. Accreditation demonstrates quality and safety standards that give buyers confidence.

State survey history. Clean survey history with no condition-level deficiencies is expected. Recent deficiencies, CMS sanctions, or compliance issues will result in either a deal failure or significant price reduction and escrow requirements.

What Kills ASC Valuations

Surgeon concentration. One or two surgeons generating 50%+ of cases creates unacceptable risk for most buyers. Diversify your surgeon panel before going to market.
Declining case volume. Year-over-year case volume decline raises immediate questions about physician engagement, competitive dynamics, and market sustainability.
Heavy Medicare/Medicaid payer mix. Centers with 60%+ government payer mix face margin compression and are less attractive to commercial buyers.
Deferred equipment investment. Aging surgical equipment, outdated anesthesia machines, or a center that hasn't been remodeled in 15 years signals deferred CapEx that buyers will deduct from valuation.
Out-of-network billing dependency. If a significant portion of revenue comes from out-of-network billing, buyers will apply a discount reflecting the regulatory and legislative risk to that revenue stream.

Preparing Your ASC for Sale

Based on the ASC transactions I've been involved with, here are the highest-impact preparation steps:

Recruit additional surgeons. Diversifying your surgeon panel reduces concentration risk and grows case volume simultaneously. Target specialties that are migrating to ASC settings — orthopedic total joints, spine, and cardiology are the growth areas.

Optimize your payer contracts. Renegotiate managed care contracts 18-24 months before sale. A 5-10% improvement in commercial rates drops directly to EBITDA and gets multiplied by your valuation multiple. On a 7x multiple, a $100K improvement in payer rates adds $700K to enterprise value.

Align physician partners on exit timing. Start conversations with your physician partners 12-18 months before engaging a banker. Achieving consensus on timing, deal structure preferences, and post-closing commitments before going to market prevents the surprises that derail processes.

Invest in quality and compliance. Maintain current accreditation, ensure clean survey history, and document quality metrics (infection rates, patient satisfaction, complication rates). Institutional buyers conduct rigorous clinical due diligence, and deficiencies discovered post-LOI create leverage for price reductions.

Explore adding high-value specialties. If you're a GI-focused ASC, recruiting an orthopedic surgeon who can bring total joint cases can transform your valuation. The higher-acuity, higher-reimbursement cases command premium multiples that can shift your center from a 5x to an 8x asset.

The Bottom Line

ASC valuation in 2026 is driven by the continued migration of procedures from hospitals to outpatient settings, aggressive competition among platform acquirers, and the fundamental economics of high-margin surgical care delivered at lower cost. Centers with diverse surgeon panels, strong commercial payer mix, high-acuity specialties, and clean regulatory records are commanding premium multiples in a market that shows no signs of cooling.

The complexity of physician syndication, regulatory requirements, and deal structure means that ASC transactions benefit enormously from experienced advisors who understand the space. Unlike selling a medical practice, where the transaction is relatively straightforward, ASC sales involve multiple stakeholders, complex operating agreements, and regulatory considerations that can make or break a deal. Plan early, align your partners, and invest in the metrics that drive value.